Peer-reviewed veterinary case report
Laser treatment for dog glaucoma using different sweep speeds
By Benitez-Vera, Valeria et al.·Published in Veterinary ophthalmology·2025·Department of Ophthalmology, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Micropulse transscleral cyclophotocoagulation in canine glaucoma: A retrospective study evaluating sweep velocity.
- Species:
- dog
Plain-English summary
A group of dogs with glaucoma underwent a new laser treatment called micropulse transscleral cyclophotocoagulation (MP-TSCP) to help lower their eye pressure. After the procedure, the dogs showed a significant drop in eye pressure, with 84% of them maintaining good control after six months. Most dogs in the slower treatment group kept their vision, while some in the faster group experienced some loss. The treatment also reduced the need for glaucoma medications, and any side effects were mild and resolved quickly. Overall, MP-TSCP proved to be a safe and effective option for managing canine glaucoma.
People also search for: dog glaucoma treatment · micropulse laser for dogs · canine eye pressure management
Abstract
OBJECTIVE: To report preliminary results of MP-TSCP in canine patients with glaucoma while evaluating sweep velocity, treatment efficacy, and safety utilizing standardized surgical parameters. ANIMAL STUDIED: Client-owned dogs that underwent MP-TSCP at a veterinary referral hospital. PROCEDURE: Medical records of 19 eyes (14 dogs) treated with MP-TSCP were reviewed. Eleven eyes were treated with a 10 s/sweep (s) velocity and 8 eyes with a 20 s/s. Laser duty cycle was set at 31.3%, mean laser energy was 2766 mW, and mean duration was 120 s per hemisphere. Minimum post-operative follow-up was 6 months. Outcomes of intraocular pressure (IOP), vision status, degree of antiglaucoma medications, and complications were evaluated. RESULTS: There was a significantly lower median (IQR) IOP (<25 mmHg) at each timepoint postoperatively compared to IOP pre-operatively (p < 0.05). The overall success rate for IOP control at 6 months was 84%, 100% for the 10 s/s and 62.5% for the 20 s/s. Vision was preserved in 10/11 (90%) eyes from the 10 s/s group and 4/8 (50%) eyes from the 20 s/s group at 6 months. Average number of glaucoma medications in the 10 s/s group decreased from 4.4 to 1.5 and from 3.3 to 2.5 in the 20 s/s group. Post-operative complications were mild and resolved within 1 week. CONCLUSIONS: MP-TSCP is a non-invasive treatment alternative for canine glaucoma. Employing higher energy levels rendered long-term IOP control while retaining a high safety profile with minimal postoperative complications. There was no statistical difference between a 10 s/s and 20 s/s surgical velocity, both leading to successful surgical outcomes up to 6 months post-operatively.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38448774/